Procter & Gamble Health Ltd - 500126 - Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited ('The Company')
Find enclosed details with respect to tax deduction at source on dividend income declared by the Company Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Find details of duplicate share certificates issued to shareholders of the Company Procter & Gamble Health Ltd - 500126 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Find enclosed annual secretarial compliance report for the Financial Year ended June 30,2023 Procter & Gamble Health Ltd - 500126 - Related Party Transaction Disclosure For The Second Half And Six Months Ended June 30,2023
Find enclosed related party transaction disclosure for the second half and six months ended June 30,2023 Procter & Gamble Health Ltd - 500126 - For The Purposes Of Annual General Meeting And Payment Of Dividend For The Year Ended June 30, 2023, If Approved By Members At The 56Th Annual General Meeting.
We would like to inform you that the 56th AGM of the Company will be held on Tuesday, November 15, 2023. We would like to inform you that the register of members and share transfer books shall remain closed from November 15,2023 to November 21,2023 for the purpose of AGM and payment of dividend for the Financial Year ended June 30,2023 Q1FY24 Quarterly & FY23 Annual Result Announced for Procter & Gamble Health Ltd.
Pharmaceuticals company Procter & Gamble Health announced Q4FY23 & FY23 results: Q4FY23: Reported a sale of Rs 306.6 crore up by about 3% versus Q4FY22. The sales grew at low single digit against the headwinds of slowing down of the category in Q4FY23. The company reported a PAT of Rs 29.8 crore, a decline of 28% against Q4FY22 on account of higher material costs and one-time employee costs. FY23: The company has recorded a strong performance with sales of Rs 1,206 crore, up by 10% vs. FY22. Profit after tax (PAT) for FY23 is Rs 229 crore, up by 19% versus FY22. The board of directors has recommended a final dividend of Rs 50 per equity share, for FY23. “We continued our efforts towards brand and category development and thus delivered a strong performance in the fiscal, marked by consistent growth across all our brands. The quarter, however, witnessed a category slowdown across our portfolio. Despite these challenges, we continued our commitment to our strategy of five integrated choices: a portfolio of daily-use products where performance drives brand choice; superiority across product, package, brand communication, retail execution, and value; productivity; constructive disruption of the entire value chain; and a highly efficient and effective organization structure. We raised awareness and education among our consumers through initiatives like Neuropathy Awareness Week, wherein leading Global Health Experts converged to address the growing Public Health Concern of Peripheral Neuropathy. This also reinforced our efforts towards building an ecosystem for scientific collaboration and knowledge-sharing among healthcare professionals. We also commemorated World Health Day by launching the Pragati Utsav, an initiative to raise awareness and empower the healthcare professionals of rural hinterlands, on Vitamin B deficiency. We bolstered our go-to-market strategy and strengthened our partnerships across omni-channel stores, increasing the availability and access of our brands across online and offline platforms, thereby helping meet the needs of our consumers and customers. We launched the first-of-its-kind policies for employees, including the end-to-end support for children with special needs and a co-pay India Day Care policy, We continued to foster an environment of equal opportunities at the workplace. SEHAT, our flagship CSR program, continued to remain a priority during this fiscal year where we continued to strengthen public health through our strategic initiatives,” said Milind Thatte, Managing Director, Procter & Gamble Health. Result PDF Procter & Gamble Health Ltd - 500126 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Find enclosed the press release regarding the audited financial results for the year ended June 30,2023 Procter & Gamble Health Ltd - 500126 - Corporate Action-Board approves Dividend
We are pleased to inform you that the Board of Directors of the Company, at its meeting held today recommended a final dividend of Rs. 50 per share for the financial year ended June 30,2023 Procter & Gamble Health Ltd - 500126 - Audited Financial Results For Financial Year Ended June 30, 2023
Find enclosed the Audited financial results for the Financial Year ended June 30,2023